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Infection with human cytomegalovirus (CMV) during pregnancy is the most common cause of congenital
disorders, and can lead to severe life-long disabilities with associated high cost of care. Since there is no
vaccine or effective treatment, current efforts are focused on identifying potent neutralizing antibodies. A
panel of CMV monoclonal antibodies identiﬁed from patent applications, was synthesized and expressed
in order to reproduce data from the literature showing that anti-glycoprotein B antibodies neutralized
virus entry into all cell types and that anti-pentameric complex antibodies are highly potent in
preventing virus entry into epithelial cells. It had not been established whether antibodies could prevent
subsequent rounds of infection that are mediated primarily by direct cell-to-cell transmission. A
thorough validation of a plaque reduction assay to monitor cell-to-cell spread led to the conclusion
that neutralizing antibodies do not signiﬁcantly inhibit plaque formation or reduce plaque size when
they are added post-infection.
& 2013 Elsevier Inc. All rights reserved.Introduction
While human cytomegalovirus (CMV) infections in healthy indi-
viduals are generally asymptomatic, infection via perinatal transmis-
sion is a major cause of birth defects and infection in
immunocompromised patients is associated with signiﬁcant morbid-
ity and mortality (Kenneson and Cannon, 2007; Grifﬁths, 2012). The
current drugs to treat CMV infections, ganciclovir, valganciclovir,
foscarnet, and cidofovir, all target the viral DNA polymerase and are
associated with teratogenicity, toxicity, carcinogenicity and/or neu-
tropenia (reviewed in Boeckh and Geballe, 2011). Due to these
signiﬁcant limitations, these drugs are not used to prevent the
transmission of CMV from mother-to-infant during pregnancy and
are only used off-label for short courses in symptomatic neonates
(Kimberlin et al., 2003). Prior CMV seroconversion of mothers is
associated with much lower rates of mother to child transmission
(Kenneson and Cannon, 2007), giving indirect evidence that anti-





maceuticals Inc., Ridgeﬁeld,possibilities such as vaccination, efforts are currently focused on
identifying potent anti-CMV monoclonal antibodies that could ﬁll
this therapeutic void presently only partially addressed by experi-
mental products such as CMV-speciﬁc hyperimmune globulins,
Cytogams or Cytotects, that have low potency and require intrave-
nous infusion (reviewed in Adler, 2012). The mechanism by which
anti-CMV antibodies prevent transmission during pregnancy is not
yet completely understood but may include direct neutralization of
extracellular virus, antibody-dependent cell-mediated cytotoxicity,
complement-dependent-cytotoxicity and perhaps inhibition of direct
virus cell-to-cell spread (Navarro et al., 1993; Andreoni et al., 2001;
Forthal et al., 2001; Burton, 2002; Frenzel et al., 2012).
Like herpes simplex virus and other well studied herpesviruses,
cell-associated CMV is known to have the ability to spread to
contiguous cells without having to transit via the extracellular
space (Kinzler and Compton, 2005; Digel et al., 2006). This direct
cell-to-cell spread of progeny virus to adjacent cells is thought to
be an important immune evasion mechanism and may have
signiﬁcant clinical implications (reviewed in Sattentau, 2008).
The identiﬁed viral proteins molecules required for this process
often correspond to those required for viral entry. Among others,
glycoprotein B (gB), glycoprotein H (gH) and glycoprotein L (gL)
have been shown to be required for cell-to-cell spread as well as
syncytia formation in many members of the herpesvirus family
including CMV (Kinzler and Compton, 2005; Isaacson and
Compton, 2009; Bowman et al., 2011). gH/gL are associated with
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glycoprotein O and UL128-131a (the latter which with gH and gL
form the pentameric complex (PC)) (Hahn et al., 2004; Wang and
Shenk, 2005; Adler et al., 2006). These viral envelope proteins
have been detected at the surface of the host cell where they likely
play a role in cell-to-cell spread of the virus (Middeldorp et al.,
1985; Jennings et al., 1987).
The importance of this dissemination mechanism is high-
lighted by the fact that despite a high tropism for many different
cell types, the extracellular virus concentration is generally very
low in CMV-infected individuals (Hamprecht et al., 1998; Kalil and
Florescu, 2009). Although CMV laboratory prototypical strains like
AD169 are highly cytopathic and rapidly shed into the supernatant
of infected cells in culture, it has been shown that clinical isolates
remain mostly cell-associated (Wang and Shenk, 2005; Sinzger
et al., 2007). Further supporting the importance of cell-to-cell
spread is a study showing that depleting blood of its peripheral
leukocytes prevents lateral transmission of the virus (Ljungman
et al., 2002).
The most evident in vitro manifestation of cell-to-cell spread is
the observation of discrete plaques on monolayers of cells grown
in vitro. Consequently, plaque reduction assays (PRA) are widely
used to evaluate the ability of antiviral agents to inhibit cell-to-cell
spread. While a standardized PRA has been employed for mon-
itoring neutralization of extracellular virus (Landry et al., 2000),
this is not the case for evaluating cell-to-cell spread of CMV.
Studies investigating the efﬁcacy of antibodies directed against
CMV surface proteins have suggested that neutralizing antibodies
can also prevent cell-to-cell spread in the PRA (Navarro et al.,
1993; Andreoni et al., 2001; Frenzel et al., 2012), while other
papers indicate that antibodies cannot prevent cell-to-cell spread
of CMV (Sinzger et al., 2007; Schroer and Shenk, 2008).
Our goal was to clarify the role of antibodies in preventing the
propagation of CMV in cell culture. We address the differences
between the procedures for monitoring cell-to-cell spread as well
as the conclusions drawn from our experiences and the literature.Results
Genetically engineered monoclonal antibodies are functional
and have neutralization potencies similar to those reported
in the literature
A panel of seven tool monoclonal antibodies (mAb), based on
patent applications, was synthesized and expressed in order toTable 1
Antibodies can neutralize CMV in an immunofocus assay.
Antibody Ag AD169/MRC5 VR1814/MRC5
EC50 EC90 EC50 EC90
Cytogam Poly 40 140 20 150
EV2038 AD1 (gB) 0.05 0.58 0.19 1.6
7H3 AD1 (gB) 0.20 0.7 0.20 2
EV2045 AD2 (gB) 0.06 0.3 0.09 0.26
ITC-88 AD2 (gB) 0.7 3.8 0.23 1.3
MSL-109 gH 0.21 4 0.15 1.7
1F11 PC 432 432 432 432
4I22 PC 432 432 432 432
All EC50 and EC90 reported as mg/ml and are the average of at least four experiments. N
a EC50 value (mg/ml).
b EC90 value (mg/ml).
c Tested on ﬁbroblasts.
d Tested on epithelial cells.recapitulate neutralization data from the literature in parallel
along with a CMV-speciﬁc hyperimmune globulin (CMV-IG) pre-
paration (Cytogams). It is important to note that this CMV-IG
preparation was selected based on high binding titers to CMV and
not for the ability to neutralize CMV. These mAb are directed
against gB, gH and PC as described in Table 1. The CMV antibodies
were tested in a microneutralization immunofocus assay with the
detection of CMV Intermediate Early 1 protein (IE1) in MRC-5
ﬁbroblasts infected either with the lab strain AD169 or the clinical
isolate VR1814, or in ARPE-19 epithelial cells infected with VR1814.
We conﬁrmed that the tool anti-gB antibodies neutralize virus
entry into all cell types at moderate potency, and that anti-PC
antibodies are highly potent in preventing virus entry into
epithelial cells but do not prevent entry into ﬁbroblasts
(Macagno et al., 2010). CMV-IG showed increased neutralization
potency on VR1814-infected ARPE-19 cells as compared with MRC-
5 cells, in agreement with the a study demonstrating the presence
of anti-PC antibodies in CMV-IG preparations (Fouts et al., 2012).
CMV-IG was not able to inhibit cell-to-cell spread in a validated
plaque reduction assay
PRAs were developed and CMV-IG was tested in parallel with
the CMV entry inhibitor CFI02 (Jones et al., 2004) and the
nucleotide analog ganciclovir (reviewed in Martin et al., 1983)
when they were added at the time of infection or 3 h post-
infection at 10x EC50, followed by agarose overlay to limit extra-
cellular spread of CMV. While all three were able to inhibit plaque
formation when added at the time of infection (in the absence of
agarose), only CFI02 and ganciclovir were able to inhibit plaque
formation when added 3 h post-infection (Fig. 1A). This was our
ﬁrst indication that while CMV-IG could neutralize virus entry, it
was not able to prevent cell-to-cell spread on subsequent rounds
of infection even when tested at 10x EC50 for neutralization of
extracellular virus.
Various measures were taken to ensure that the monitoring of
plaque reduction reﬂected cell-to-cell spread inhibition and not
inhibition of infection of contiguous cells via extracellular release
of CMV. There was no shift in potency for GCV when it was added
at the time of infection or 3 h post-infection (Fig. 1A, EC50 2.2–
6.8 mM against the different virus/cell combinations tested). CFI02
had very similar potency of 1–4 mM when added at the time of
infection or 3 h post-infection on VR1814-infected MRC-5 and
ARPE-19 cells. However CFI02 showed a 10-fold decrease in
potency when added 3 h post-infection of AD169-infected MRC-
5 cells (t¼0 EC50 0.2 mM; t¼3 h EC50 1.5 mM) (Fig. 1A, Table 2). ThisVR1814/ARPE19 Reported potency Reference
EC50 EC90
1.2 5 40a,c Planitzer et al. (2011)
0.2 1.2 0.027a,c, 0.040a,d Takada et al. (2010a)
0.2 0.8 3b,c, 0.6b,d Macagno et al. (2010)
0.05 0.3 0.061a,c, 0.053a,d Takada et al. (2010b)
0.16 0.67 1–2a,c Ohlin et al. (1993)
0.13 0.6 1.4a,c Nokta et al. (1994)
0.00024 0.0011 NNb,c, 0.001b,d Macagno et al. (2010)
0.0003 0.0014 NNb,c, 0.0015b,d Macagno et al., 2010
N: Non neutralizing.
Table 2
Antiviral potency of CFI02 and Ganciclovir in CMV plaque reduction assays with
and without CMV-IG in the overlay.













CFI02 1.5 1.5 1.3 2.4 3.9 5.2
Ganciclovir 2.2 2.8 6.8 4.2 6.4 4.0
EC50 are the average of two experiments.
Table 3
Number of plaques with and without CMV-IG in the agarose overlay in the plaque
reduction assays.
Virus/Cell 7 day incubation 14 day incubation
No CMV-IG CMV-IG 2xEC90 No CMV-IG CMV-IG 2xEC90
AD169/MRC-5 38 39 ND 42
VR1814/MRC-5 38 35 36 40
VR1814/ARPE-19 39 38 39 40
Average plaque count for two wells from one experiment. This experiment was
repeated 6 times ending at 7 days post-infection, and two times ending at 14 days
post-infection.
ND: not determined. See Fig. 1B for micrograph.
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entry inhibitor where a decrease in potency was also seen in a cell-
to-cell spread assay of AD169-infected ﬁbroblasts (Jones et al.,
2004), but it also could be due to transmission of extracellular
virus in the PRA. It should be noted that VR1814 forms syncytia,
while the lab strain AD169 does not (Wang and Shenk, 2005). It
has also been shown that CMV entry into endothelial and
epithelial cells requires UL128 to UL150, and that this is not
required for entry of AD169 into ﬁbroblasts (Ryckman et al.,
2006). It is possible that CFI02 inhibits entry by binding to the
pentameric complex in addition to gB. The addition of CMV-IG to
the agarose overlay at a concentration sufﬁcient to neutralize all
extracellular virus (2x EC90) in liquid culture did not alter the EC50
of GCV and CFI02 obtained in the absence of CMV-IG (Table 2).
This suggests that neutralization of extracellular virus, if any, does
not inﬂuence the readout of the PRA at 7 days incubation.
To better understand the contribution of extracellular virus to
the number and size of the plaques, 10xEC90 CMV-IG was added in
the overlay at 3 h post-infection, and the plates were incubated for
7 (as usual) or 14 days, and then ﬁxed and stained (Fig. 1B). The
plaques were then counted and their size was determined. The
number of plaques counted with and without CMV-IG with every
cell/virus combinations at 7 days incubation is similar (Table 3). As
shown in Fig. 1C, the size of plaques after 7 days for AD169 and
VR1814 were not different whether CMV-IG was added to the
overlay or not. This was also true for VR1814 on both cell lines at
14 days incubation. However, wells infected with AD169 without
CMV-IG at 14 days post-infection contained large and poorly
deﬁned plaques that merged, making counting impossible,
whereas the plaques in the presence of CMV-IG were still well
deﬁned (Fig. 1B). These results indicate that AD169 and VR1814
were mainly transmitted from cell-to-cell in our PRA format for up
to 7 days post-infection. While VR1814 was still transmitted cell-
to-cell at 14 days post-infection, AD169 appeared to be spread
both intracellularly and extracellulary as evidenced by the restric-
tion of plaque growth in the presence of CMV-IG at this later
time point. Moreover, this also demonstrated that antibodies
are still functional in the agarose overlay at both 7 and 14 dayspost-infection. Taken together, these data validate our assay
format of examining plaque reduction at 7 days incubation in
order to monitor cell-to-cell spread.Monoclonal antibodies were not able to prevent cell-to-cell spread
in PRA
Experiments were performed with tool mAb in the PRAs with
AD169 and VR1814 on MRC-5 and ARPE-19 cells. While mAb were
able to inhibit plaque formation completely when added at the
time of infection, they were not able to inhibit at 3 h post-infection
at 10x their EC50 (Fig. 2A). A time of addition study in the PRA was
performed with CMV-IG, EV2045 (α-gB) and 4I22 (α-PC) where
they were added at time 0, 1, 2 and 3 h after CMV infection at 2x
their EC90. Successively less inhibition of plaque formation was
seen over the time course from 70 to 100% reduction at time zero,
to 0% reduction at 3 h post-infection (Fig. 2B), suggesting that the
extent of inhibition of plaque formation correlates with the
inhibition of the initial viral entry at time zero. Therefore, both
mAb and CMV-IG were not able to inhibit cell-to-cell spread
of CMV.Comparison of methods to monitor cell-to-cell viral spread
A cell-to-cell spread assay with the addition of antibody at
different times post-infection was performed in order to replicate
the observations found with EVEC2038 where 75–100% inhibition
of plaque formation was observed with 40.63 mg/ml when anti-
body is added 24 h post-infection (Takada et al., 2010a, 2012). The
method used in this application relies on replenishment of the
media containing the antibody every 24 or 48 h (Navarro et al.,
1993). A condition in which the mAb was added at time zero was
also tested. The addition of EV2038 at 24 h post-infection did not
reduce plaque formation (Fig. 3A).
A PRA was also performed with CMV-IG (10x EC90) and EV2038
and ITC-88 (10 mg/ml) using a method similar to that described
previously (Frenzel et al., 2012) and compared to our in-house
assay. In this method, cells were infected for 1 h by spinoculation
and washed before adding the overlay with the antibody and
incubating for 7 days. Modest to no reduction in plaque formation
was seen when antibody was added at 1 h post-infection, whereas
90% inhibition was seen when antibody was added at t¼0 during
spinoculation (AD169: Fig. 3B, VR1814: data not shown). Overall
examination of the various PRA methods led to the conclusion that
the CMV antibodies were not able to prevent plaque formation
when added post-infection.Ab could not inhibit plaque formation even when cells
were not conﬂuent
A PRA was performed to assess the inﬂuence of the density of
cells seeded on the ability of EV2038 to inhibit plaque formation.
In papers indicating that antibodies can inhibit plaque formation
(Navarro et al., 1993; Frenzel et al., 2012) no speciﬁc detail was
given on cell seeding density. It is possible that Ab could inhibit
cell-to-cell spread if viral proteins are expressed and neutralized at
the cell membrane before contacting the membranes of adjacent
cells. Four different cell seeding densities were tested (10–85%
conﬂuency) and the antibody was added at the time of infection or
3 h post-infection. No inhibition was observed when the antibody
was added at 3 h post-infection, independent of the cell density
(Fig. 4). These results suggest that the cell conﬂuency did not
inﬂuence the ability of EV2038 to inhibit plaque formation.
Fig. 1. CMV-IG does not prevent cell-to-cell spread in a plaque reduction when added after initial cycle of infection. (A) PRA was performed where CMV-IG, CFI02 and GCV at
10x EC50 were added at t¼0, and/or t¼3 h post-infection with agarose overlay. (B) Phase-contrast micrograph of AD169-infected MRC-5 cells at 7 and 14 days post-infection
with and without CMV-IG at 2x EC90 added at 3 h post-infection with the agarose overlay. (C) No difference was seen in plaque size measured at 7 days with and without
CMV-IG at 10x EC50. PRA was performed as described and CMV-IG was added with overlay at 3 h post-infection and size of plaques was determined at 7 days post-infection
by measuring the average size of 20 plaques using the Harmony software.
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There are multiple steps where congenital infection could be
blocked during the process from primary infection of the mother
to transmission to the fetus. There are three main ways that viral
spread could be prevented: direct neutralization of extracellular
virus, prevention of cell-to-cell spread, and, the destruction of
infected cells that express the viral antigens at their surface
through antibody effector function. Data from this present study
and the literature demonstrate that CMV-speciﬁc antibodiesagainst gB, gH and PC can neutralize extracellular virus and
prevent viral entry in relevant cell lines using both immunofocus
neutralization assays and plaque reduction assays (PRA) when
antibody is added during the ﬁrst cycle of infection (Ohlin et al.,
1993; Nokta et al., 1994; Macagno et al., 2010; Takada et al., 2010a,
2010b, 2012; Planitzer et al., 2011).
However, it was not clear from previous studies if antibodies
could prevent subsequent rounds of infection that are mediated
primarily by direct cell-to-cell transmission. While on ﬁrst glance
it did not appear possible for antibodies, due to their size and
Fig. 2. CMV monoclonal antibodies do not prevent cell-to-cell spread in PRA when added 3 h post-infection. (A) Comparison of antibodies (10xEC50) added at t¼0, and/or
t¼3 h post-infection with agarose overlay in PRA. (B) Addition of CMV-IG and EV2045 (2xEC90) at t¼0, 1, 2 and/or t¼3 h post-infection with agarose overlay in PRA.
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in the literature indicated that CMV antibodies were capable of
preventing this mode of transmission in cultured ﬁbroblasts
(Navarro et al., 1993; Frenzel et al., 2012; Takada et al., 2012).
This is in contrast to other studies where CMV-IG was speciﬁcally
used in media to prevent extracellular spread without affecting
cell-to-cell transmission (Silva et al., 2005; Ryckman et al., 2006;
Schroer and Shenk, 2008; O'Connor and Shenk, 2011). Moreover,
sera from CMV-infected patients was used to demonstrate
that while lab isolates of CMV show both intracellular and
extracellular spread in vitro, CMV clinical isolates are strictly cell-
associated and therefore inaccessible to neutralizing antibodies
(Sinzger et al., 2007).
In our hands, CMV-IG and a panel of neutralizing mAb to CMV
envelope proteins were not able to inhibit plaque formation when
added 3 h post-infection with both a lab and a clinical isolate on
ﬁbroblasts and epithelial cells. Concentrations up to 1.5 mg/ml
CMV-IG and 10 mg/ml mAb were tested. The latter concentration
corresponds to the range of IgG seen in gB-speciﬁc antibodies
in vivo (Ohlin et al., 1997). We validated our PRA by testing small
molecule inhibitors with and without CMV-IG and monitoring
plaque count and size over the duration of the assay (7 days) and
beyond (14 days).
It was reported that CMV-IG could inhibit plaque formation of
lab and most clinical isolates on ﬁbroblasts at 2 mg/ml when it
was added 1 h after spinoculation (Frenzel et al., 2012). EV2038, a
gB mAb, has been shown to inhibit plaque formation of AD169 onﬁbroblasts at concentrations as low as 0.63 mg/ml when added
24 h post-infection (Takada et al., 2012). Our data is in contrast to
what has been reported, therefore we sought to compare multiple
methods for monitoring cell-to-cell spread of CMV. We saw no
inhibition of plaque formation by 10 mg/ml EV2038 when added
24 h post-infection and replenished every 24 or 48-h as per the
published protocol (Navarro et al., 1993). We also saw modest to
no reduction of plaque formation when antibody was added at 1 h
post-infection by spinoculation as per published protocol (Frenzel
et al., 2012), whereas 90% inhibition was seen when antibody was
added at the same time as infection. The inhibition of plaque
formation was not enhanced by a 30 min incubation with anti-
bodies at room temperature prior to the application of the agarose
overlay (data not shown), suggesting that antibodies only inhibit
the initial entry of virus. It should be noted that in the latter
published method, Avicels was used and not agarose, although
this is unlikely to explain the differences seen in the results.
Furthermore, we have demonstrated that antibodies are still
functional when added in the agarose overlay as evidenced by
discrete plaques being seen after 14 days of infection of MRC-5
cells with AD169 in the presence of CMV-IG, versus cytopathic
effect being observed in the absence of CMV-IG.
The in vivo situation is more complicated than cell culture
models of monolayers of ﬁbroblasts or epithelial cells. Studies have
been conducted with polarized cells to bridge this gap. It has been
reported that CMV-speciﬁc mAbs failed to inhibit CMV transmis-
sion across lateral membranes of polarized ARPE-19 epithelial cells
Fig. 3. CMV antibodies are not active in various PRA methodologies when added
after initial cycle of infection. (A) EV2038 (10 mg/ml) was added at t¼0 (Method A
0 h), t¼24 h and replenished every 24 h (Method B 24 h), or at t¼24 h and
replenished every 48 h (Method B 48 h) in cell-to-cell spread assay (without
agarose). (B) CMV-IG (10xEC90) or CMV monoclonal antibodies (10 mg/ml) were
added at t¼0 or t¼3 post-infection, agarose was overlaid at t¼3 h and plaques
were detected at 7 days post-infection (Method A). The CMV antibodies were also
added at t¼0 or after 1 h spinoculation at room temperature followed by the
application of agarose overlay containing CMV-speciﬁc antibodies as above
(Method C). Plaques were visualized at 7 days post-infection as described in
Materials and Methods.
Fig. 4. Activity of CMV monoclonal antibody is not affected by conﬂuency of cells.
EV2038 (10 mg/ml) was added at t¼0 and/or t¼3 h post-infection with agarose
overlay on cells seeded at different densities (cells/well) in PRA.
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no data was presented on cell conﬂuency in the monolayer
cultures where inhibition of cell-to-cell spread was reported for
CMV antibodies (Navarro et al., 1993; Frenzel et al., 2012; Takada
et al., 2012), we found that cell conﬂuency did not inﬂuence the
inability of a CMV mAb to inhibit plaque formation.Overall, we performed a thorough validation of our CMV PRA to
monitor inhibition of cell-to-cell viral spread and an in-depth
comparison to two other methods. Our data conﬁrms several
publications in the literature and leads to the conclusion that
CMV-speciﬁc neutralizing antibodies do not signiﬁcantly inhibit
plaque formation or reduce plaque size when they are added post-
infection.Materials and methods
Cells and viruses
MRC-5 (lung ﬁbroblast) and ARPE-19 (retinal pigmented
epithelium) were obtained from ATCC (CCL-171 and CRL-2302,
respectively). MRC-5 cells were used between passages 18 and 29
and were grown in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% Penicillin–Streptomycin (DMEM: Invitrogen
11995; FBS: Hyclone SH30396-03; Penicillin–Streptomycin: Invi-
trogen, 15140163). ARPE-19 cells were cultured in DMEM/F12 (1:1,
Invitrogen, 11320033) supplemented with 10% fetal bovine serum
and 1% Penicillin–Streptomycin. All assays are performed using
culture media supplemented with 5% FBS and 1% Penicillin–
Streptomycin (assay media) to allow an increased infectivity of
the virus.
CMV strain AD169 was obtained from ATCC (VR-538). VR1814
was kindly provided by Giuseppe Gerna (Servizio di Virologia,
Fondazione IRCCS Policlinico San Matteo, Italy) (Revello et al.,
2001). The viruses were propagated on MRC-5 cells for ampliﬁca-
tion until a complete cytopathic effect was observed. The culture
harvest was clariﬁed by centrifugation at 1000g, and titered by
immunofocus assay. Brieﬂy, virus was serially diluted 1/10 and
used to infect 96-well plates of MRC-5 (3104 cells/well) or ARPE-
19 cells (3104 cells/well) for 16–18 h at 37 1C and 5% CO2.
Infected cells were detected with anti-CMV staining and counted
as described below in the neutralization assay protocol.Antibodies
All monoclonal antibody sequences were obtained from Seq IDs
in patent applications (see Supplemental Data Table S1 for more
details). The DNA was synthesized by a contract research organi-
zation. The CMV antibody genes were removed from the commer-
cial vectors by enzymatic digestion; puriﬁed, and cloned into IgG
expression plasmids. The IgG clones were transfected into HEK293
cells with heavy and light chain DNA clones, using 293fectin (Life
Technologies). The cells were harvested 6 days post-transfection
for antibody puriﬁcation. MabSelectSure (GE Healthcare) columns
were equilibrated with Dulbecco's PBS. The clariﬁed culture super-
natant was loaded onto the equilibrated columns, washed 3X with
wash buffer (DPBS/DPBS with 1 M NaCl/DPBS), then eluted with
30 mM sodium acetate pH 3.5. All the eluted fractions were pooled
together and the pH was adjusted to 5 in 60 mM sodium acetate
buffer.
Cytogams was obtained as a Cytomegalovirus Immune Globu-
lin Intravenous solution from CSL Behring (50 mg Ig/ml).Compounds
Ganciclovir was purchased from Sigma-Aldrich (G5236) and
CFI02 was kindly provided by Dr. Lee Fader, Boehringer Ingelheim
(Canada) Ltd.
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In a 384-deep well plate, antibodies were serially diluted
2.5 fold in columns 2 to 11 and 14 to 23 in the appropriate assay
media. Assay media containing no antibody was added in column
1, 12, 13 and 24. 20 ml of the dilutions was transferred in duplicate
to a black 384-well plate with a clear bottom (Greiner, GR781091).
CMV was diluted to yield a concentration of 5104 IU/ml and
20 ml of the virus inoculum was added to columns 12 and 24 (0%
inhibition) as well as to the wells containing the diluted anti-
bodies. Assay media without virus was added in column 1 and 13
(100% inhibition). This mixture was incubated for 2 h at 37 1C, 5%
CO2. 2.25104 cells/well prepared in 40 ul of assay media were
added to the antibody/virus mixture to yield a ﬁnal 0.04 IU/cell.
The plates were brieﬂy centrifuged for 10 s at 233g and incubated
for 16 to 18 h at 37 1C, 5% CO2. The following day, the plates were
washed once with PBS and ﬁxed with an acetone/methanol
solution (1:1). After a 10 min incubation at room temperature,
the ﬁxing solution was discarded and the plates were left to dry
for 10 min. The plates were then stained for 90 min with 1 mg/ml
of anti immediate-early protein 1 (IE1) Alexa Fluor 488-conjugated
antibody (Millipore, MAB810X) in PBS containing 2% normal goat
serum (Medicorp, 005-000-121). To control for variations in cell
number across wells cells were stained with 2.5 mg/ml of Hoechst
33342 nuclear dye (Invitrogen, H3570). The plates were washed
3 times with PBS and the plates were covered with a Top Seal ﬁlm
(PerkinElmer, 6005185) and ﬂuorescent images were acquired
using the Operetta (PerkinElmer) high content screening system
as described below.Plaque reduction assay
Method A
The method is an adaptation of the plaque reduction assay
described previously (Landry et al., 2000). Brieﬂy, 1.4105 cells/
well were seeded in a Costar clear 24 well plate (Corning Costar,
3526) in 500 ml of cell culture media and incubated for 18 to 20 h
at 37 1C, 5% CO2. Cells were then infected at an MOI of approxi-
mately 0.0008 IU/cell in a total of 250 ml for 3 h at 37 1C, 5% CO2 on
a rocking plate. The inoculum was aspirated and cells were
overlaid with a mixture of 600 ml of 0.8% agarose maintained at
45 1C in a water bath and 600 ml of room temperature 2x DMEM
+10% FBS containing the appropriate antibody or compound
dilution. The plates were then incubated for 6 to 8 days at 37 1C
with 5% CO2 (AD169 on MRC-5: 6 to 7 days; VR1814 on MRC-5 or
ARPE-19, 7 to 8 days). After the incubation, the agarose overlays
were removed and the cell layers were washed once with PBS
before being ﬁxed with acetone/methanol (1:1) for 10 min. The
ﬁxing solution was then removed and the plates were left to dry
for 2–3 min. The cells were then stained with 1 mg/ml of IE1-Alexa
Fluor 488-conjugated antibody in PBS with 2% normal goat serum
for 1 h. Following anti-IE1 staining, cells were washed 3 times
with PBS and the and the plates were covered with a Top Seal ﬁlm
and ﬂuorescent images were acquired using the Operetta high
content screening system as described below.Method B
The cell seeding and infection was carried out as in method A.
However, an agarose overlay was not used to limit extracellular
virus propagation. Instead, following the aspiration of the inocu-
lum, fresh assay media was added and antibodies were replen-
ished every 24 or 48 h.Method C
Two aspects were modiﬁed from method A. The infection was
carried out by centrifugation at 600g for 60 min at room tempera-
ture. The plates were then further incubated for 30 min at room
temperature in the presence or absence of antibody before repla-
cing inoculum with the agarose overlay and antibody preparation.
Immunoﬂuorescence data capture
Fluorescent images were acquired for the stained plates using
the Operetta high content screening system and images were
analyzed using the Harmony software (PerkinElmer). The Har-
mony software was set to recognize a plaque based on the number
of infected nuclei present and a plaque was deﬁned as45 adjacent
infected nuclei. The IFA neutralization and PRA results were
expressed as percent inhibition relative to the untreated unin-
fected wells (100% inhibition) and untreated infected wells (0%
inhibition). The EC50 curves were calculated with Assay Explorer
(Accelrys) using the best curve ﬁt.Acknowledgments
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